<?xml version="1.0" encoding="UTF-8"?>
<search_results count="22">
  <query>Olysio + Sovaldi</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT02206932</nct_id>
    <title>A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV CDC Category A1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir + Simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMC435HPC2008</other_id>
    </other_ids>
    <first_received>July 30, 2014</first_received>
    <last_updated>November 21, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 (HCV RNA &lt;LLOQ, or lower limit of quantification)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02206932</url>
  </study>
  <study rank="2">
    <nct_id>NCT02165189</nct_id>
    <title>An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitits C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Scientific Affairs, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR104281</other_id>
      <other_id>TMC435HPC2009</other_id>
    </other_ids>
    <first_received>June 10, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>October 21, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>GALAXY</acronym>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 12 Weeks of end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response After 4 Weeks of end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis C Symptom and Impact Questionnaire Version 4 (HCV-SIQv4) Score at Week 24 (for Arms 1 and 2) and Week 36 (for Arm 3)</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Questionnaire Score at Weeks 4, 8, 12, 16, 20, 24 (for all treatment arms) and Week 36 (for Arm 3)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02165189</url>
  </study>
  <study rank="3">
    <nct_id>NCT02624063</nct_id>
    <title>Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir + Sofosbuvir</intervention>
      <intervention type="Drug">Simeprevir + Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federal University of São Paulo</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>394</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TNT</other_id>
    </other_ids>
    <first_received>December 2, 2015</first_received>
    <start_date>December 2015</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>December 3, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Sustained Virologic Response at Follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Rapid Virologic Response at Week 4 (RVR)</outcome_measure>
      <outcome_measure>Percentage of Subjects With End of Treatment Response (EOTR)</outcome_measure>
      <outcome_measure>Treatment safety measured by the number of incidence of serious adverse event (SAEs), discontinuations due to adverse event (AEs), Grade 3/4 AEs and Grade 3/4 clinical laboratory abnormalities through the end of treatment.</outcome_measure>
      <outcome_measure>Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Non-cirrhotic Subjects With Relapse at Follow-up Week 12 (SVR12)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02624063</url>
  </study>
  <study rank="4">
    <nct_id>NCT02262728</nct_id>
    <title>An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105028</other_id>
      <other_id>TMC435HPC2010</other_id>
    </other_ids>
    <first_received>October 6, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>January 2020</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR 4 Weeks After end of Study Drug Treatment (SVR4) and SVR 24 Weeks After end of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants with On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants with Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in HCV NS3/4A Sequence, NS5A and NS5B at Day 3, Week 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, and Year 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 After end of Treatment in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Percentage of Participants with Normalized Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</outcome_measure>
      <outcome_measure>Time to Reach Maximum Plasma Concentration (Tmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-Time Curve from Time 0 to 24 hours After Dosing (AUC[0-24]) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Pre-dose (trough) Concentration (C0h) of Simeprevir, Daclatasvir, Sofosbuvir and GS-331007 (Sofosbuvir metabolite)</outcome_measure>
      <outcome_measure>Percentage of Participants with SVR12 who Maintain to have HCV RNA &lt;LLOQ Until the end of 5 years Follow up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02262728</url>
  </study>
  <study rank="5">
    <nct_id>NCT02250807</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 4 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105429</other_id>
      <other_id>TMC435HPC3021</other_id>
      <other_id>2014-003446-27</other_id>
    </other_ids>
    <first_received>September 24, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>September 25, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response (SVR 12) at Week 12 After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Virologic Response at Week 4 (SVR 4) and 24 (SVR 24) After EOT</outcome_measure>
      <outcome_measure>Percentage of Subjects With On-treatment Virologic Response of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Subjects With on-treatment failure along with Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Subjects With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02250807</url>
  </study>
  <study rank="6">
    <nct_id>NCT02253550</nct_id>
    <title>Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Peter J. Ruane, M.D.</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
      <collaborator>Peter J. Ruane, M.D., Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMC435HPC2012</other_id>
    </other_ids>
    <first_received>September 17, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>June 20, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 Weeks after Treatment Completion (SVR12)</outcome_measure>
      <outcome_measure>Sustained Virologic Response 4 and 24 Weeks after Treatment Completion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02253550</url>
  </study>
  <study rank="7">
    <nct_id>NCT02114177</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR103430</other_id>
      <other_id>TMC435HPC3017</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 4 Weeks After the Planned end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 24 Weeks After the Planned end of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants with Viral Breakthrough</outcome_measure>
      <outcome_measure>Number of Participants with Viral Relapse</outcome_measure>
      <outcome_measure>Change from Baseline in Hepatitis C Symptom and Impact Questionnaire (HCV-SIQ) scores</outcome_measure>
      <outcome_measure>Change From Baseline in Fatigue Severity Scale (FSS) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 Dimension (EQ-5D) Questionnaire Scores</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02114177</url>
  </study>
  <study rank="8">
    <nct_id>NCT02114151</nct_id>
    <title>Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR103431</other_id>
      <other_id>TMC435HPC3018</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>April 2015</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned end of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 4 Weeks After the Planned end of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a Sustained Virologic Response 24 Weeks After the Planned end of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants Achieving a On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Number of Participants with Viral Breakthrough</outcome_measure>
      <outcome_measure>Number of Participants with Viral Relapse</outcome_measure>
      <outcome_measure>Change from baseline in Hepatitis C Symptom and Impact Questionnaire (HCV-SIQ) scores</outcome_measure>
      <outcome_measure>Change From Baseline in Fatigue Severity Scale (FSS) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in Center for Epidemiologic Studies Depression Scale (CES-D) Scores</outcome_measure>
      <outcome_measure>Change From Baseline in EuroQol 5 Dimension (EQ-5D) Questionnaire Scores</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02114151</url>
  </study>
  <study rank="9">
    <nct_id>NCT02168361</nct_id>
    <title>The SIM-SOF Trial for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa-2b</intervention>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Center For Hepatitis C, Atlanta, GA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHC-21</other_id>
    </other_ids>
    <first_received>June 17, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>June 19, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response 12 (SVR-12)</outcome_measure>
      <outcome_measure>Virologic Relapse</outcome_measure>
      <outcome_measure>Virologic Breakthrough</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02168361</url>
  </study>
  <study rank="10">
    <nct_id>NCT02278419</nct_id>
    <title>An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>63</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR104970</other_id>
      <other_id>TMC435HPC2014</other_id>
    </other_ids>
    <first_received>October 28, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>September 25, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 After End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 4 After End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 24 After End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With on-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02278419</url>
  </study>
  <study rank="11">
    <nct_id>NCT02349048</nct_id>
    <title>Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir 150 mg</intervention>
      <intervention type="Drug">Daclatasvir 60 mg</intervention>
      <intervention type="Drug">Sofosbuvir 400 mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR105963</other_id>
      <other_id>TMC435HPC2013</other_id>
    </other_ids>
    <first_received>January 22, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>November 19, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ACCORDION-1</acronym>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 12 Weeks After end of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 Weeks (SVR4) and 24 Weeks (SVR24) After end of Study Drug Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change from Baseline in HCV Nonstructural Protein 3/4A (NS3/4A), NS5A and NS5B Sequence in Participants not Achieving SVR</outcome_measure>
      <outcome_measure>Percentage of Participants With or Without an NS3 Q80K Polymorphism at Baseline Achieving SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>North Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02349048</url>
  </study>
  <study rank="12">
    <nct_id>NCT02485080</nct_id>
    <title>Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>PT-NANBH</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>33431</other_id>
    </other_ids>
    <first_received>June 23, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>September 15, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR) HCV RNA PCR &lt;25 IU/mL 12 weeks post-treatment</outcome_measure>
      <outcome_measure>Serious adverse events, adverse events grade 3 and above</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02485080</url>
  </study>
  <study rank="13">
    <nct_id>NCT02421211</nct_id>
    <title>A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir (SMV)</intervention>
      <intervention type="Drug">Ledipasvir (LDV)</intervention>
      <intervention type="Drug">Sofosbuvir (SOF)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Sciences Ireland UC</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR106992</other_id>
      <other_id>TMC435HPC2017</other_id>
      <other_id>2015-000459-25</other_id>
    </other_ids>
    <first_received>April 15, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of Simeprevir and Ledipasvir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Simeprevir and Ledipasvir</outcome_measure>
      <outcome_measure>Area Under the Curve Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Simeprevir and Ledipasvir</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-emergent Grade 1-4 Laboratory Abnormalities</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants with Sustained Viral Response 4 Weeks After the Actual EOT (SVR4) and 12 Weeks After Actual EOT (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Change From Baseline in HCV Nonstructural Protein (NS3/4A), Nonstructural Protein 5A (NS5A) and Nonstructural Protein 5B (NS5B) Sequence in Participants not Achieving SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02421211</url>
  </study>
  <study rank="14">
    <nct_id>NCT02455167</nct_id>
    <title>Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprivir (SMV)</intervention>
      <intervention type="Drug">Sofosbuvir (SOF)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>Janssen Scientific Affairs, LLC</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-0919</other_id>
      <other_id>UL1TR001082</other_id>
    </other_ids>
    <first_received>April 21, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 2, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation</outcome_measure>
      <outcome_measure>Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02455167</url>
  </study>
  <study rank="15">
    <nct_id>NCT02214420</nct_id>
    <title>SMV + SOF With/Without RBV for IFN-II Patients With CHC</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Simeprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SC Liver Research Consortium, LLC</lead_sponsor>
      <collaborator>Janssen, LP</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PJPIIS-01-14</other_id>
    </other_ids>
    <first_received>August 8, 2014</first_received>
    <start_date>October 2014</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>November 27, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02214420</url>
  </study>
  <study rank="16">
    <nct_id>NCT02485262</nct_id>
    <title>Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir and simeprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Regional Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1234</other_id>
      <other_id>14-25</other_id>
    </other_ids>
    <first_received>June 19, 2015</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>June 29, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR 12</outcome_measure>
      <outcome_measure>Safety and Tolerability as measured by the number of participants with AEs, Change in baseline laboratory results</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02485262</url>
  </study>
  <study rank="17">
    <nct_id>NCT02470858</nct_id>
    <title>Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF+ASV</intervention>
      <intervention type="Drug">SOF+DCV+SMV</intervention>
      <intervention type="Drug">SOF+DCV+ASV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Emory University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_Triple Therapy_1</other_id>
    </other_ids>
    <first_received>June 5, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment.</outcome_measure>
      <outcome_measure>HCV RNA levels and change during and after treatment.</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02470858</url>
  </study>
  <study rank="18">
    <nct_id>NCT02057003</nct_id>
    <title>Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Human Immunodeficiency Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAA against HCV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
      <collaborator>Hospital Universitario Reina Sofia</collaborator>
      <collaborator>Hospital Universitario Virgen de la Victoria</collaborator>
      <collaborator>Hospital Universitario de la Princesa</collaborator>
      <collaborator>Hospitales Universitarios Virgen del Rocío</collaborator>
      <collaborator>Hospital Universitario Carlos Haya</collaborator>
      <collaborator>Hospital Torrecárdenas</collaborator>
      <collaborator>Complejo Hospitalario Universitario de Huelva</collaborator>
      <collaborator>Hospital Puerta del Mar</collaborator>
      <collaborator>Hospital Universitario Virgen Macarena</collaborator>
      <collaborator>Hospital de La Línea</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR-DAA</other_id>
    </other_ids>
    <first_received>January 6, 2014</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients who achieve SVR to DAA-based therapy as measure of efficacy</outcome_measure>
      <outcome_measure>Number of patients who develop severe adverse events as measure of safety</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to a BOC-based regimen as compared to numbers of patients who achieve SVR to a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who reach undetectable HCV-RNA at week 4 of PI-based therapy as a measure of on-treatment response to therapy.</outcome_measure>
      <outcome_measure>Number of patients who develop adverse events during a BOC-based regimen as compared to numbers of patients who develop adverse events during a TVR-based regimen.</outcome_measure>
      <outcome_measure>Number of patients who achieve SVR to an interferon-free regimen.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057003</url>
  </study>
  <study rank="19">
    <nct_id>NCT02583685</nct_id>
    <title>Switching Regimen in Treating Cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 12 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 12 wk</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_SWITCH-1</other_id>
    </other_ids>
    <first_received>October 12, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWITCH-1</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Change in health related quality of life evaluated with questionnaires</outcome_measure>
      <outcome_measure>Change in mental health evaluated with questionnaires</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02583685</url>
  </study>
  <study rank="20">
    <nct_id>NCT02333292</nct_id>
    <title>Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">SMV</intervention>
      <intervention type="Drug">DCV</intervention>
      <intervention type="Drug">LED</intervention>
      <intervention type="Drug">PTV/OTV</intervention>
      <intervention type="Drug">DBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GEHEP-MONO</other_id>
    </other_ids>
    <first_received>December 15, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FPSMON201401</acronym>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Patients with Sustained Virological Response</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events</outcome_measure>
      <outcome_measure>Identification of predictors of SVR</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients that receive methadone maintenance therapy</outcome_measure>
      <outcome_measure>Analyze efficacy and safety according to previous treatment outcome</outcome_measure>
      <outcome_measure>Analyze efficacy and safety in patients with cirrhosis</outcome_measure>
      <outcome_measure>Evaluate impact of SVR on biological, elastographical and clinical parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02333292</url>
  </study>
  <study rank="21">
    <nct_id>NCT02531269</nct_id>
    <title>Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
      <collaborator>Basel Institute of Clinical Epidemiology (BICE)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-319</other_id>
    </other_ids>
    <first_received>August 11, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR4</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>On-treatment Virological response at week 4 assessed by measuring viral load</outcome_measure>
      <outcome_measure>Virological response at the end of treatment (EOT) assessed by measuring viral load</outcome_measure>
      <outcome_measure>The occurrence of virological failure (on-treatment and relapse) assessed by measuring viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02531269</url>
  </study>
  <study rank="22">
    <nct_id>NCT02393365</nct_id>
    <title>Prevalence and Screening of Hepatitis C in Belgium in 2015</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire</intervention>
      <intervention type="Procedure">HCV serology</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brugmann University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHUB-HCV screening</other_id>
    </other_ids>
    <first_received>March 9, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>July 16, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV risk factors questionnaire</outcome_measure>
      <outcome_measure>Positive/Negative Hepatitis C serology</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02393365</url>
  </study>
</search_results>
